1.31

9.03% -0.13

After Hours: 1.30 -0.01 -0.76%

Xilio Therapeutics Inc (XLO)

Overview News Price History Financials Discussions Forecast

Xilio Therapeutics Inc stock is traded at $1.31, with a volume of 409.66K. It is down -9.03% in the last 24 hours and up +67.95% over the past month. Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Previous Close:

$1.44

Open:

$1.45

24h Volume:

409.66K

Relative Volume:

1.83

Market Cap:

$59.56M

Revenue:

Net Income/Loss:

$-81.22M

P/E Ratio:

-0.4267

EPS:

-3.07

Net Cash Flow:

$-74.41M

1W Performance:

+32.32%

1M Performance:

+67.95%

6M Performance:

+11.02%

1Y Performance:

-45.42%

1-Day Range:

$1.25

$1.45

1-Week Range:

$1.035

$1.54

52-Week Range:

$0.49

$2.593

Xilio Therapeutics Inc Stock (XLO) Company Profile

Name

Xilio Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (680)

Phone

617-833-1027

Address

828 WINTER STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2024-11-09

Latest SEC Filings

XLO's Discussions on Twitter

Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-21-22	Initiated	Chardan Capital Markets	Buy
Jan-10-22	Initiated	H.C. Wainwright	Buy
Nov-16-21	Initiated	Cowen	Outperform
Nov-16-21	Initiated	Guggenheim	Buy
Nov-16-21	Initiated	Morgan Stanley	Overweight
Nov-16-21	Initiated	Raymond James	Outperform

View All

Xilio Therapeutics Inc Stock (XLO) Latest News

Oct 30, 2024

Xilio Therapeutics to Present Initial Phase 1C Dose - GlobeNewswire

Oct 30, 2024

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewswire Inc.

Oct 30, 2024

Oct 25, 2024

Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth - Simply Wall St

Oct 25, 2024

Oct 04, 2024

Xilio Therapeutics Announces Upcoming Poster Presentation - GlobeNewswire

Oct 04, 2024

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of - The Bakersfield Californian

Oct 04, 2024

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - StockTitan

Oct 04, 2024

Oct 02, 2024

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ForexTV.com

Oct 02, 2024

Sep 23, 2024

XOS stock touches 52-week low at $4.62 amid market challenges - Investing.com

Sep 23, 2024

XBP stock plunges to 52-week low at $1.05 amid market challenges - Investing.com

Sep 23, 2024

XPEV: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle

Sep 23, 2024